Login to Your Account

Neurochem Gets 2nd Approvable For Kiacta; Analysts Pessimistic

By Trista Morrison

Thursday, July 19, 2007
Almost a year after Neurochem Inc. received its first approvable letter for Kiacta (eprodisate) in the treatment of AA amyloidosis, history repeated itself. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription